CA2105538A1 - Differentially Expressed Leishmania Genes and Proteins - Google Patents

Differentially Expressed Leishmania Genes and Proteins

Info

Publication number
CA2105538A1
CA2105538A1 CA2105538A CA2105538A CA2105538A1 CA 2105538 A1 CA2105538 A1 CA 2105538A1 CA 2105538 A CA2105538 A CA 2105538A CA 2105538 A CA2105538 A CA 2105538A CA 2105538 A1 CA2105538 A1 CA 2105538A1
Authority
CA
Canada
Prior art keywords
differentially expressed
proteins
leishmania
genes
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2105538A
Other languages
French (fr)
Other versions
CA2105538C (en
Inventor
Gregory Matlashewski
Hugues Charest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Priority to CA002105538A priority Critical patent/CA2105538C/en
Publication of CA2105538A1 publication Critical patent/CA2105538A1/en
Application granted granted Critical
Publication of CA2105538C publication Critical patent/CA2105538C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Differentially expressed Leishmania genes and proteins are described. One differentially expressed gene (A2) is expressed at significantly elevated levels (more than about 10 fold higher) in the amastigote stage of the life cycle when the Leishmania organism is present in macrophages than in the free promastigote stage. The A2 gene encodes a 22 kD protein (A2 protein) that is recognized by kala-azar convalescent serum and has amino acid sequence homology with an S-antigen of Plasmodium falciparum Vietnamese isolate VI. Differentially expressed Leishmania genes and proteins have utility as vaccines, diagnostic reagents, as tools for the generation of immunological reagents and the generation of attenuated variants of Leishmania.
CA002105538A 1993-09-03 1993-09-03 Differentially expressed leishmania genes and proteins Expired - Fee Related CA2105538C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002105538A CA2105538C (en) 1993-09-03 1993-09-03 Differentially expressed leishmania genes and proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002105538A CA2105538C (en) 1993-09-03 1993-09-03 Differentially expressed leishmania genes and proteins

Publications (2)

Publication Number Publication Date
CA2105538A1 true CA2105538A1 (en) 1995-03-04
CA2105538C CA2105538C (en) 1999-03-09

Family

ID=4152261

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002105538A Expired - Fee Related CA2105538C (en) 1993-09-03 1993-09-03 Differentially expressed leishmania genes and proteins

Country Status (1)

Country Link
CA (1) CA2105538C (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826018A1 (en) * 2001-06-18 2002-12-20 Pasteur Institut Tunis New virulence-associated protein from Leishmania, useful in protective vaccines, is a protein disulfide isomerase, also related nucleic acid, antibodies and inhibitors
WO2005021030A1 (en) * 2003-08-29 2005-03-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Live attenuated leishmania vaccines
US7700121B2 (en) 2001-06-18 2010-04-20 Institut Pasteur Gene associated with leishmania parasite virulence

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826018A1 (en) * 2001-06-18 2002-12-20 Pasteur Institut Tunis New virulence-associated protein from Leishmania, useful in protective vaccines, is a protein disulfide isomerase, also related nucleic acid, antibodies and inhibitors
WO2002103002A3 (en) * 2001-06-18 2004-02-26 Pasteur Institut Tunis Gene associated with leishmania parasite virulence
US7700121B2 (en) 2001-06-18 2010-04-20 Institut Pasteur Gene associated with leishmania parasite virulence
US8715697B2 (en) 2001-06-18 2014-05-06 Institut Pasteur De Tunis Genes associated with Leishmania parasite virulence
WO2005021030A1 (en) * 2003-08-29 2005-03-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Live attenuated leishmania vaccines
US7887812B2 (en) 2003-08-29 2011-02-15 The United States Of America As Represented By The Department Of Health And Human Services Live attenuated Leishmania vaccines
US8877213B2 (en) 2003-08-29 2014-11-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Live attenuated Leishmania vaccines

Also Published As

Publication number Publication date
CA2105538C (en) 1999-03-09

Similar Documents

Publication Publication Date Title
AU7529194A (en) Differentially expressed (leishmania) genes and proteins
IE822517L (en) Human immune interferon
GR3029983T3 (en) Diagnosis of leishmaniasis.
IL70776A (en) Recombinant dna molecule encoding at least one polypeptide displaying the immunogenicity of at least one merozoite antigen or asexual blood stage antigen of p.falciparum,vectors comprising the dna molecule,host cells transformed thereby,immunogenic polypeptides produced by host cells and compositions containing the polypeptides
AU7319194A (en) Nucleotide and amino acid sequences of the envelope 1 gene of 51 hepatitis c virus isolates and the use of reagents derived therefrom as diagnostic reagents and vaccines
AU1026692A (en) Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
CA2263889A1 (en) P-selectin ligand proteins
CA2065287A1 (en) New hcv isolates
DE3586801D1 (en) SYNTHETIC HEPATITIS B VIRUS VACCINE CONTAINING T CELL AND B CELL DETERMINERS.
CA2018273A1 (en) Thermally stable cytosine deaminase
AU1463097A (en) Helicobacter pylori bacterioferritin
CA2186423A1 (en) Protein which induces interferon-gamma production by immunocompetent cell
CA2105538A1 (en) Differentially Expressed Leishmania Genes and Proteins
WO1995030001A3 (en) Novel p-selectin ligand protein
AU1516392A (en) Cloned glutamic acid decarboxylase
NZ233328A (en) Polypeptides produced by hepatocytes infected with p. falciparum; nucleic acid probes
AU1321988A (en) The cloning of malaria-specific dna sequences: isolation of the gene for the 140 kd protein
DE3683261D1 (en) PLASMODIUM-FALCIPARUM-ANTIGEN OF THE INTRAERYTHROCYTA PHASE, ITS CLEANING AND DETERMINATION OF ANTIQUE AND ANTIBODY AND MALARIA VACCINES CONTAINING IT.
BR0208140A (en) Polypeptide, immunotherapeutic agent for the treatment of psoriasis, isolated nucleic acid sequence or complement, single-stranded and double-stranded vectors, isolated nucleic acid sequence or immunogenic variant thereof, methods for the production of polypeptides, and for treatment and clinical remission of psoriasis, and, microbial host cell
WO1990000179A3 (en) Novel proteins, dna coding for said proteins, and their use
AU6687786A (en) Asexual blood stage antigens of plasmodium falciparum
Winchell S-antigens of Plasmodium falciparum: their origin, stage-specificity and biochemical nature.
AU7698287A (en) Small molecular weight antigen of plasmodium falciparum
KR920016593A (en) Plasmodium falciparum blood-stage antigen, method for preparing and use thereof
TH3879A (en) Malaria vaccine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed